Clinic
Crimson Urgent Care, LLC
Crimson Urgent Care, LLC was paid $1.45M by Medicaid between Jan 2018 and Dec 2024, across 41 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 24% of everything it billed.
33Billing provider infoCRIMSON URGENT CARE, LLC
TUSCALOOSA, AL 35404
TUSCALOOSA, AL 35404
33aNPI1831205228assigned 08/21/2006
33bProvider typeUrgent Care Clinic/Center
28Total paid$1.45M
24GClaims71,603
24DCodes billed41
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Urgent Care Clinic/Center providers in Alabama
Rank by total paid#5 of 59
Median peer was paid$77K
This provider vs. median19×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 110 | $816.13 | |
| 2019 | 131 | $667.20 | |
| 2020 | 8,338 | $191K | |
| 2021 | 15,665 | $317K | |
| 2022 | 18,044 | $338K | |
| 2023 | 19,054 | $456K | |
| 2024incomplete | 10,261 | $147K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 24% | 7,955 | 6,677 | $355K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 22% | 5,057 | 4,193 | $316K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 14% | 2,863 | 2,619 | $206K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 6.8% | 5,784 | 5,230 | $99K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 5.4% | 11,887 | 5,116 | $79K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 4.8% | 634 | 574 | $69K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 4.0% | 2,455 | 2,053 | $58K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | 3.4% | 1,325 | 1,141 | $49K |
| 87428 | 3.0% | 1,040 | 937 | $44K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 2.9% | 5,094 | 4,300 | $42K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | 2.5% | 2,355 | 1,811 | $36K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 2.0% | 3,194 | 2,804 | $29K |
29 more codes
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.3% | 533 | $18K |
| 71046 | Radiologic examination, chest; 2 views | 1.2% | 1,196 | $18K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 5,372 | $13K |
| 87807 | <1% | 712 | $5K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 684 | $4K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,953 | $3K |
| 81002 | <1% | 1,263 | $2K | |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 16 | $2K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 997 | $1K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,750 | $985.11 |
| 81025 | <1% | 320 | $599.79 | |
| 81003 | <1% | 74 | $114.00 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 84 | $110.93 |
| S0077 | Injection, clindamycin phosphate, 300 mg | <1% | 34 | $43.12 |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | <1% | 630 | $0.52 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 681 | $0.14 |
| 3079F | 0% | 78 | $0.00 | |
| 2010F | 0% | 396 | $0.00 | |
| 3074F | 0% | 353 | $0.00 | |
| 1170F | 0% | 667 | $0.00 | |
| 3008F | 0% | 539 | $0.00 | |
| 3080F | 0% | 25 | $0.00 | |
| 2001F | 0% | 531 | $0.00 | |
| 1160F | 0% | 538 | $0.00 | |
| A7003 | Administration set, with small volume nonfiltered pneumatic nebulizer, disposable | 0% | 349 | $0.00 |
| 1159F | 0% | 539 | $0.00 | |
| 3078F | 0% | 244 | $0.00 | |
| 1494F | 0% | 390 | $0.00 | |
| 3077F | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialPERAMSETTY, SASANK (MEDICAL DIRECTOR)
| Provider | Location | Paid |
|---|---|---|
| Crimson Care LLC | Tuscaloosa, AL | $1.50M |
| First Kids | Tuscaloosa, AL | $1.35M |
| First Care LLC | Tuscaloosa, AL | $812K |
| Alabama Family Medical Center, LLC | Tuscaloosa, AL | $168K |
| Crimson Care North | Northport, AL | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.